Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

被引：0
|
作者：
David Elsea
Lin Fan
Adela Mihai
Fadoua El Moustaid
Daniel Simmons
Matthew Monberg
Dominic Muston
机构：
[1] Formerly of Lumanity,
[2] Inc.,undefined
[3] Formerly of Merck & Co.,undefined
[4] Inc.,undefined
[5] AstraZeneca,undefined
[6] AstraZeneca,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
PharmacoEconomics - Open | 2022年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：811 / 822
页数：11
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
    Elsea, David
    Fan, Lin
    Mihai, Adela
    El Moustaid, Fadoua
    Simmons, Daniel
    Monberg, Matthew
    Muston, Dominic
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 811 - 822
  • [2] Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
    David Elsea
    Lin Fan
    Adela Mihai
    Fadoua El Moustaid
    Daniel Simmons
    Matthew Monberg
    Dominic Muston
    [J]. PharmacoEconomics - Open, 2022, 6 : 899 - 899
  • [3] Olaparib in combination with bevacizumab compared to bevacizumab monotherapy for the first-line maintenance treatment of advanced ovarian cancer: a cost-effectiveness analysis
    Fan, Lin
    Muston, Dominic
    Elsea, David
    El Moustaid, Fadoua
    Mihai, Adela
    Simmons, Daniel
    McLaurin, Kimmie
    Monberg, Matthew
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S216 - S217
  • [4] Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer (Aug, 10.1007/s41669-.022-.00338-2, 2022)
    Elsea, David
    Fan, Lin
    Mihai, Adela
    Moustaid, Fadoua El
    Simmons, Daniel
    Monberg, Matthew
    Muston, Dominic
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (06) : 899 - 899
  • [5] Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy
    Cedillo, Sergio
    Gari, Carla
    Aceituno, Susana
    Manso, Luis
    Lleti, Ana Cristina Cercos
    Bosch, Pedro Ventayol
    Casado, Antonio
    Fidalgo, Alejandro Perez
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (02) : 277 - 284
  • [6] An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer
    Wolford, J. E.
    Liang, S. Y.
    Tewari, K. S.
    Eskander, R. N.
    Kapp, D. S.
    Mann, A. K.
    Chan, J. K.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 25 - 25
  • [7] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [8] COST-EFFECTIVENESS OF OLAPARIB PLUS BEVACIZUMAB FIRST-LINE MAINTENANCE IN OVARIAN CANCER ALONGSIDE THE PAOLA-1 TRIAL
    Perrier, L.
    Zarca, K.
    Cadet, T.
    Morelle, M.
    Cropet, C.
    Burges, A.
    Cecere, S. C.
    Palacio, I
    Polterauer, S.
    Yoshida, H.
    Vuylsteke, P.
    Colombo, N.
    Nottrup, T. J.
    Abdeddaim, C.
    El-Balat, A.
    Cinieri, S.
    Herrero, A.
    Kaminski, M. C.
    Pujade-Lauraine, E.
    Durand-Zaleski, I
    Ray-Coquard, I
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S61 - S62
  • [9] Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis
    Zhu, Youwen
    Yang, Qiuping
    Liu, Kun
    Cao, Hui
    Zhu, Hong
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (01)
  • [10] FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
    Arora, Shaily
    Balasubramaniam, Sanjeeve
    Zhang, Hui
    Berman, Tara
    Narayan, Preeti
    Suzman, Daniel
    Bloomquist, Erik
    Tang, Shenghui
    Gong, Yutao
    Sridhara, Rajeshwari
    Turcu, Francisca Reyes
    Chatterjee, Deb
    Saritas-Yildirim, Banu
    Ghosh, Soma
    Philip, Reena
    Pathak, Anand
    Gao, Jennifer J.
    Amiri-Kordestani, Laleh
    Pazdur, Richard
    Beaver, Julia A.
    [J]. ONCOLOGIST, 2021, 26 (01): : E164 - E172
12345